Abstract: There is provided a duplexer having first, second and third ports and adapted for connection between an antenna and uplink and downlink, respectively, in a full duplex communication system. The duplexer has first and second quarter wave transformers connected between the first and third and between the first and second ports, respectively. The duplexer has a balancing resistor connected between the third port and the output of the second transformer. The duplexer has a filter circuit connected between the output of the second transformer and the second port.

Abstract: A wireless communication system has a base station operative to communicate wirelessly with a plurality of customer devices. The base station has a circulator with a first port connected to one or more signal transmission devices, a second port that is connected to one or more antennas, and a third port that is connected to one or more signal reception devices. The circulator communicates transmission signals from the one or more signal transmission devices to the one or more antennas, and communicates received signals from the one or more antennas to the one or more signal reception devices. The plurality of customers devices have cancellation/separation duplexers or circulators.

Abstract: There is provided a duplexer having first, second and third ports and adapted for connection between an antenna and uplink and downlink, respectively, in a full duplex communication system. The duplexer has first and second quarter wave transformers connected between the first and third and between the first and second ports, respectively. The duplexer has a balancing resistor connected between the third port and the output of the second transformer. The duplexer has a filter circuit connected between the output of the second transformer and the second port.

Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted ?-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Abstract: This invention provides for method for the treatment, prevention or ameliorating the symptoms of nonalcoholic fatty liver disease (NAFLD) in a mammal in need thereof comprising the step of administering an effective amount of a composition comprising a therapeutic combination of at least one cholesterol lowering agent and/or at least one H3 antagonist/inverse agonist.

Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Abstract: The present invention is directed to pharmaceutical compositions comprising a sterol absorption inhibitor, a CEPT inhibitor and/or an HMG-CoA reductase inhibitor as well as methods for treating sitosterolemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, mixed dyslopidemia, vascular events prevention and related disorders in a mammal in need thereof by administering said pharmaceutical compositions to the mammal.

Abstract: The present invention provides therapeutic combinations and methods including at least one sterol or 5?-stanol absorption inhibitor that can be useful for treating xanthomas and hypercholesterolemia.

Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted ?-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Abstract: The present invention provides methods for the treatment of obesity using sterol or 5?-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5?-stanol absorption inhibitors and at least one obesity control medication.

Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Abstract: The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.